Details of the Drug Combination

General Information of Drug Combination (ID: DCZ9CJN)

Drug Combination Name
Linezolid Tazobactam
Indication
Disease Entry Status REF
Bacterial Pneumonia Phase 3 [1]
Component Drugs Linezolid   DMGFPU2 Tazobactam   DM3XNUI
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Linezolid
Disease Entry ICD 11 Status REF
Bacteremia 1A73 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Staphylococcal pneumonia N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Skin infection 1F28-1G0Z Investigative [2]
Linezolid Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial 23S ribosomal RNA (Bact 23S rRNA) TTLFGBV NOUNIPROTAC Binder [7]
------------------------------------------------------------------------------------
Linezolid Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Decreases Activity [8]
Amine oxidase B (MAOB) OTTDFM1O AOFB_HUMAN Decreases Activity [8]
------------------------------------------------------------------------------------
Indication(s) of Tazobactam
Disease Entry ICD 11 Status REF
Appendicitis DB10 Approved [5]
Bacterial infection 1A00-1C4Z Approved [6]
Peritonitis N.A. Approved [5]
Staphylococcus aureus infection N.A. Approved [5]
Pelvic inflammatory disease GA05 Investigative [5]
Tazobactam Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus Beta-lactamase (Stap-coc blaZ) TTHI19T BLAC_STAAU Inhibitor [9]
------------------------------------------------------------------------------------
Tazobactam Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEEZ5CV BLO1_KLEOX Metabolism [10]
Beta-lactamase (blaB) DEYIEO5 AMPC_SERMA Metabolism [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02493764) Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
2 Linezolid FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 200222.
4 Therapeutic and Triage Strategies for 2019 Novel Coronavirus Disease in Fever Clinics. Lancet Respir Med. 2020 Mar;8(3):e11-e12.
5 Tazobactam FDA Label
6 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
7 Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
8 Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol. 2021 May 17;34(5):1348-1354. doi: 10.1021/acs.chemrestox.0c00524. Epub 2021 Apr 29.
9 Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
10 Characterization of piperacillin/tazobactam-resistant klebsiella oxytoca recovered from a nosocomial outbreak. PLoS One. 2015 Nov 5;10(11):e0142366.
11 Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.